BIOVECTRA acquired by AGILENT TECHNOLOGIES

Bansk Group completed the acquisition of 100% of PetIQ in an all-cash public-to-private transaction. PetIQ was delisted from Nasdaq upon closing and is now operated as a privately held company, with founder Cord Christensen continuing as CEO. The existing executive management team will continue to operate the business independently. The strategic rationale centres on accelerating PetIQ's mission of providing convenient and affordable pet healthcare, investing in marketing and innovation, and pursuing strategic bolt-on acquisitions — initiatives that Bansk believes are better executed outside the constraints of public market ownership.

Anjac reorganized its capital by welcoming KKR and Krefeld as minority shareholders, following a competitive process led by Rothschild & Co. The EUR450M investment allowed the exit of historical partners Andera Partners, Bpifrance, and IDIA. The Anjac family maintains a strong majority. The transaction was coupled with an extension of the existing syndicated credit line to fund future acquisitions.

Nordson Corporation completed its acquisition of Atrion Corporation on August 21, 2024, following the definitive agreement announced on May 28, 2024. The strategic rationale is centered on portfolio expansion within Nordson Medical. Atrion adds proprietary infusion fluid delivery and niche cardiovascular technologies, broadening Nordson’s exposure to adjacent end markets and strengthening its offering in higher-growth medical applications. The combination is highly complementary from both a product and customer standpoint, while also benefiting from Atrion’s FDA-registered manufacturing footprint and patent portfolio. This creates a more comprehensive platform with meaningful cross-sell and integration potential. From a value creation perspective, the transaction supports Nordson’s long-term growth framework by increasing exposure to secular healthcare demand, recurring single-use consumables, and OEM outsourcing trends. Management also highlighted anticipated operational synergies over the first two years of ownership, which should enhance the deal’s attractiveness and support margin expansion over time.

The acquisition of the point-of-care technology platform from the LumiraDx group marks a transformative technical reinforcement of the acquirer's diagnostic ecosystem. The strategic rationale for this transaction centers on a "decentralization" play, merging the target's innovative multi-assay hardware with the group’s vast global commercial and R&D infrastructure. This fusion effectively creates a comprehensive solution set for primary care and remote settings, addressing the global need for timely and affordable diagnostic results outside of centralized facilities. This operation allows for a definitive structural expansion of the group's "patient-centric" vision, covering the entire journey from general practitioner offices to remote healthcare outposts. By incorporating a platform capable of handling diverse modalities (including coagulation and future molecular testing) the organization can now provide a more robust and integrated service for infectious disease management, such as tuberculosis detection in partnership with global health foundations. The maneuver optimizes the group's positioning in low- and middle-income countries where traditional laboratory access is limited. Ultimately, the partnership solidifies the group’s standing as a primary enabler of community-based healthcare innovation, bridging the gap between sophisticated laboratory diagnostics and industrialized point-of-need testing standards.

GTCR agreed to acquire Surmodics as a take-private acquisition, financed through committed equity from GTCR-affiliated funds and committed debt financing. The strategic rationale rests on Surmodics’ position as a specialized healthcare technology platform with recurring exposure to medical device coatings and in vitro diagnostics. The business has a long track record of serving blue-chip customers, and its proprietary technologies are aligned with secular healthcare growth drivers including aging demographics, minimally invasive procedures, and OEM outsourcing. For GTCR, the asset fits a classic platform investment profile, offering a combination of technical differentiation, market defensibility, and scope for operational value creation. The deal also has a clear sector consolidation angle. Surmodics’ coating expertise and medical device capabilities could support future expansion across adjacent applications, while GTCR’s healthcare focus may allow it to back strategic growth initiatives and build further scale.

The successful acquisition of ELITechGroup by Bruker Corporation marks a definitive tactical expansion of the group's microbiology and infection diagnostics portfolio. This transaction facilitates the integration of ELITech’s innovative sample-to-result molecular diagnostic systems with Bruker’s existing microbial identification capabilities. The strategic rationale for the move centers on the fusion of ELITech’s specialized PCR assay technology and Bruker’s global reach and industrialized R&D machine. The operation should reinforce Bruker's ability to address the increasing demand for decentralized, high-accuracy testing in infectious disease management. The partnership is designed to leverage Bruker’s extensive distribution network to accelerate the penetration of the BeGenius® platform into larger North American and Asian hospital markets. This integration facilitates the creation of a more robust technological platform, providing the strategic depth required to navigate the maturing landscape of automated clinical diagnostics. The move solidifies Bruker’s standing as a primary enabler of molecular precision and time-critical diagnostic innovation globally, while securing a resilient, consumables-driven financial profile.

Kühne Holding AG has entered into a definitive agreement to acquire a majority stake in Aenova Group from the international investment firm BC Partners. In a move to ensure continuity and strategic alignment, funds advised by BC Partners will reinvest alongside Kühne Holding to maintain a minority position in the company. The transaction was structured and executed in close partnership with E3X Partners, acting as the lead advisor and investment partner for the Kühne family vehicle. The strategic rationale for the acquisition is focused on expanding Kühne Holding’s portfolio into the pharmaceutical services sector, attracted by Aenova’s strong financial foundation and long-term growth prospects. Under BC Partners' ownership, Aenova achieved record financial results and established itself as a top-ten global CDMO. The new ownership structure is designed to transition the company from a traditional private equity cycle to a long-term "evergreen" investment horizon, providing the stability needed to build highly sought-after technology platforms and specialized development services.

The acquisition of Peters Surgical by Advanced Medical Solutions Group plc is a strategic move to expand AMS's portfolio of surgical products and strengthen its presence in the global wound closure and tissue repair market. The transaction will enable Peters Surgical to benefit from complementary product portfolios, sales forces, commercial presence, and distribution networks. The acquisition is expected to create a leading player in the advanced wound closure and surgical closure market, with a comprehensive portfolio of products and a strong global presence. The combined entity will have increased direct sales capabilities in key markets, including France, the USA, Germany, India, Poland, and Belgium, and will be well-positioned to capitalize on cross-selling and upselling opportunities. The acquisition is subject to approval by the French authorities and is expected to be completed in 2024.

Merck has entered into a definitive agreement to acquire 100% of the outstanding shares of Harpoon Therapeutics. Strategically, this acquisition allows Merck to further diversify its oncology pipeline by integrating Harpoon’s proprietary TriTAC and ProTriTAC T-cell engager platforms. The rationale for the deal centers on the potential of the lead candidate, HPN328, which targets DLL3 in small cell lung cancer and neuroendocrine tumors, providing Merck with a highly complementary asset for its existing immunotherapy portfolio. This move is a classic example of a "platform-driven" acquisition where a large-cap pharmaceutical player secures innovative R&D capabilities and preclinical assets to reinforce its therapeutic leadership. From a transaction facts perspective, the deal will be accounted for as an asset acquisition, with a non-GAAP charge of approximately $650 million expected upon closing.

Marle Group has acquired Nowak from a consortium of private equity investors led by Siparex Midcap, alongside Bpifrance, Unexo, and the management team. This acquisition strengthens Marle's vertical integration by adding specialized casting capabilities. The deal follows a successful transformation period under Siparex (2018-2023), where Nowak shifted its focus toward the medical sector and acquired Belmonte. The transaction was financed via a unitranche debt facility provided by Capza.